We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
药物asundexian（拜耳）获得FDA优先审评资格，用于预防复发性卒中。风险降低26%，且未增加出血风险。OCEANIC-STROKE研究详情。
